MCM
TYRA icon

MAI Capital Management’s Tyra Biosciences TYRA Stock Holding History

MAI Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$154 Buy
+4
New +$129 ﹤0.01% 4671

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

MAI Capital Management's TYRA Position: Q1 2026 in Review

MAI Capital Management opened a new position in Tyra Biosciences (TYRA) in Q1 2026: 4 shares worth $154. The stake represents ﹤0.01% of the portfolio and ranks #4671 among its holdings.

164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • MAI Capital Management held 4 shares of Tyra Biosciences worth $154 as of Q1 2026.
  • Tyra Biosciences was a new MAI Capital Management position in Q1 2026.
  • Tyra Biosciences made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4671 holding.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.